Document is current
Any future updates will be listed below
-
Authors
Schmalhofer, Marie-Lena https://orcid.org/0000-0003-4991-8544
Farschtschi, Said https://orcid.org/0000-0002-3596-5932
Kluwe, Lan https://orcid.org/0000-0001-9919-4551
Mautner, Victor Felix
Adam, Gerhard https://orcid.org/0000-0001-7976-3868
Well, Lennart https://orcid.org/0000-0003-2491-1346
Ristow, Inka https://orcid.org/0000-0002-3032-2321
- License Information
-
More Information
Article History
Received: 22 August 2024
Accepted: 13 October 2024
First Online: 4 November 2024
Declarations
:
: This study protocol has been approved by the local Institutional Review Board (Ärztekammer Hamburg; 2023-300412-WF; app. date 23.11.2023) for retrospective analysis of the available data which complied with the Declaration of Helsinki.
: Written informed consent was given from all NF1 patients at the initial consultation at the neurofibromatosis clinic for the anonymized analysis and scientific use of the MRI data.
: SF and LW have received honoraria for talks and advisory from AstraZeneca and Alexion and SF is chairman of the German lay organization “Bundesverband Neurofibromatose”.
